Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Valeant ups offer for Salix, Endo throws in the towel

This article was originally published in Scrip

Executive Summary

Valeant Pharmaceuticals has agreed an increased all-cash offer price for Salix Pharmaceuticals of $173 per share, up from its earlier $158 offer, prompting Endo International to pull out of the bidding war for the gastro-intestinal products specialist.

You may also be interested in...

Stockwatch: Uncertainty Trumps Earnings Seasons Fundamentals

A post-US election relief rally was magnified in life science stocks last week and swept away poor third-quarter earnings results at Valeant, Endo, AstraZeneca and Impax.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts